Welcome to our dedicated page for Forte Biosciences SEC filings (Ticker: FBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Forte Biosciences, Inc. filings document a clinical-stage biopharmaceutical issuer focused on FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases. Its 8-K reports cover operating and financial results, Regulation FD clinical disclosures, material events, capital-structure matters and exhibits such as press releases and clinical presentations.
Proxy materials describe annual meeting matters, stockholder voting, board and compensation governance and equity incentive plan administration. The filing record also identifies Forte’s common stock, par value $0.001 per share, listed on Nasdaq under the symbol FBRX.
Brun Scott C. reported acquisition or exercise transactions in this Form 4 filing.
Forte Biosciences, Inc. director Scott C. Brun reported receiving a grant of 18,353 restricted stock units (RSUs) tied to the company’s common stock. Each RSU represents a contingent right to receive one share of Forte common stock.
The award vests in full at the first annual stockholder meeting that occurs after May 29, 2026, as long as Brun continues serving as a “Service Provider” under the company’s 2021 Equity Incentive Plan through that date. Following this grant, he holds 18,353 RSUs directly, reflecting equity-based compensation rather than an open‑market purchase or sale.
Kornfeld Steven reported acquisition or exercise transactions in this Form 4 filing.
Forte Biosciences, Inc. director Steven Kornfeld received a grant of restricted stock units as equity compensation. He was awarded 18,353 RSUs, each representing one share of common stock at a price of $0.00 per unit. Following this award, he holds 18,353 RSUs directly.
According to the grant terms, 100% of these RSUs will vest on the date of the first annual stockholder meeting that occurs after May 29, 2026, provided he continues as a Service Provider under the company’s 2021 Equity Incentive Plan through that date.
Forte Biosciences, Inc. reported results of its 2026 annual stockholder meeting, where stockholders approved an amended and restated 2021 Equity Incentive Plan reserving 5,190,000 shares of common stock for equity awards. The plan allows stock options, stock appreciation rights, restricted stock, restricted stock units, performance units and performance shares for employees, directors and consultants.
As of the April 17, 2026 record date, 20,478,817 shares were outstanding, and 17,766,034 shares were represented at the May 29, 2026 meeting in person or by proxy. Stockholders also elected three directors and approved additional proposals including the equity plan described in the company’s April 29, 2026 proxy statement.
Forte Biosciences, Inc. Schedule 13G/A shows OrbiMed Advisors LLC beneficially owns 884,230 shares of common stock (4.3%) and OrbiMed Capital LLC beneficially owns 312,725 shares (1.5%). The reporting persons state they aggregate 5.8% of the class held on behalf of other persons and that investment and voting power is exercised through a management committee of Carl L. Gordon, Sven H. Borho, and W. Carter Neild.
The filing discloses voting and dispositive power split: OrbiMed Advisors reports shared voting and shared dispositive power over 884,230 shares; OrbiMed Capital reports sole voting and sole dispositive power over 312,725 shares. Signatures are dated 05/15/2026.
Forte Biosciences, Inc. Schedule 13G/A amendment shows that Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen reported 0% beneficial ownership of Forte Biosciences common stock as of the close of business on March 31, 2026. The filing lists the reporting persons' principal business address and CUSIP 34962G208.
Forte Biosciences, Inc. ownership filing: MPM BioImpact LLC reports beneficial ownership of 1,000,682 shares of common stock, representing 7.2% of the class as reported in the filing. The filing shows sole voting and dispositive power over these shares. The signature date is 05/15/2026.
Alger Associates, Inc. amended its Schedule 13G to report beneficial ownership of 1,272,596 shares of Forte Biosciences common stock, equal to 10.2% of the class. The filing states these shares are held in open-end investment companies and managed accounts of Fred Alger Management, LLC, a wholly owned subsidiary of Alger Group Holdings, LLC, which in turn is a subsidiary of Alger Associates, Inc. The filing lists sole voting power of 1,268,303 shares and sole dispositive power of 1,272,596 shares. Signature date is 05/15/2026.
Janus Henderson Group plc reports beneficial ownership of common stock in FORTE BIOSCIENCES, INC. The filing states the Asset Managers under Janus Henderson beneficially hold 1,387,178 shares of common stock, representing 9.99% of the class. The filing also lists 299,798 pre-funded warrants that cannot be exercised to the extent they would result in ownership over 9.99%. The disclosure describes investment and voting discretion exercised on behalf of managed client portfolios.
Forte Biosciences reported a larger first quarter 2026 net loss while advancing its lead drug candidate FB102. The company posted a net loss of $22.1 million, or $(1.24) per share, compared with a $15.7 million loss a year earlier, driven mainly by higher research and development spending.
Research and development expenses rose to $20.5 million, largely from FB102 Phase 2 celiac disease and Phase 1b vitiligo and alopecia areata trials, while general and administrative costs declined to $2.0 million helped by a $2.3 million interim legal settlement payment from an insurance carrier.
The FDA granted FB102 Fast Track Designation in celiac disease, and Forte highlighted upcoming topline data for Phase 1b vitiligo and Phase 2 celiac disease studies. The company held $58.2 million in cash and cash equivalents at March 31, 2026 and subsequently raised $172.5 million in gross proceeds in an April equity offering, issuing 6.6 million additional common shares.
Affinity Asset Advisors, LLC and Michael Cho report beneficial ownership of 1,011,890 shares of Forte Biosciences common stock, representing approximately 7.3% of the outstanding shares as of March 31, 2026. The filing cites 13,885,668 shares outstanding as of March 27, 2026, per the issuer's Form 10-K.
The shares are held directly by Affinity Healthcare Fund, LP; Affinity Asset Advisors serves as the fund's investment manager and exercises sole voting and dispositive power over the reported shares. The amendment is signed by the reporting persons and dated May 14, 2026.